End-stage renal disease

Also called ESRD

There are 892 papers on end-stage renal disease in aging research: 99 trials and 571 observational studies in people, 7 in animals, 3 in cells, 189 reviews. The newest story, Nov 14, 2026: “Early-life sugar rationing linked to lower kidney disease risk”.

Disease

892 papers study it219 more mention it148 findings

63 new papers in 30 daysSee all 1,112 papers on end-stage renal disease

“In the pooled analysis using 11 trials (SGLT2i = 25,907, placebo = 20,811), there was a substantial decline in the development of ESKD in patients under SGLT2i treatment relative to the placebo group (RR = 0.70, 95% CI: 0.65 to 0.75, I2 = 0.0%, p = 0.92, ).”
Effectiveness of SGLT2 inhibitors in slowing chronic kidney disease progression and reducing mortality: a meta-analysisFrontiers in pharmacology2026doi:10.3389/fphar.2026.1923548
  • Human trial99
  • Humans571
  • Animals7
  • Cells3
  • In silico12

Interventions

8

GLP-1 receptor agonists

no changein humans2HR 0.781–0.92

2 studies
  1. GLP-1 receptor agonists were not clearly linked with end-stage renal disease in humans (Cardiovascular risk factors without established ASCVD) (HR 0.92, 95% CI 0.783–1.069).

    “ESRD rates were similar at 1 year (HR 0.92; 0.783-1.069)”

    HumansCardiovascular risk factors without established ASCVD1 year

    Blood sugar drugs linked to fewer heart and blood vessel events

    AHA Scientific Sessions 2026 abstract

  2. GLP-1 receptor agonists were not clearly linked with end-stage renal disease in humans (compared with SGLT2 inhibitors) (HR 0.781 (95% CI 0.397-1.537), p=0.121).

    “new ESRD requiring dialysis (HR:0.781,95% CI: 0.397-1.537, p=0.121)”

    Humanscompared with SGLT2 inhibitorsfemalesn = 815

    Efficacy of GLP-1 Receptor Agonists VS SGLT2 Inhibitors on Cardiovascular Outcomes in Women with Type 2 Diabetes and Premature Coronary Artery Disease: A Propensity Score Matched Analysis

    AHA Scientific Sessions 2025 abstract

More on GLP-1 receptor agonists

GLP-1 receptor agonists + SGLT2 inhibitors

no changein humans1

1 study
  1. GLP-1 receptor agonists + SGLT2 inhibitors were not clearly linked with end-stage renal disease in humans.

    “No significant differences were observed for myocardial infarction, cerebral infarction, or end-stage renal disease.”

    HumansHeart transplant recipients with type 2 diabetes mellitus and/or BMI ≥35 kg/m 2; compared with SGLT2 inhibitor therapy aloneUp to 3 yearsn = 256

    Peri-Transplant SGLT2 Inhibitor Plus GLP-1 Receptor Agonist Therapy versus SGLT2 Inhibitor Therapy Alone and Outcomes After Heart Transplantation in Patients with Type 2 Diabetes Mellitus and/or BMI ≥35 kg/m ²

    AHA Scientific Sessions 2026 abstract

More on GLP-1 receptor agonists + SGLT2 inhibitors

Intensive blood pressure control

no changein humans1HR 1.05

1 study
  1. Intensive blood pressure control was not clearly linked with end-stage renal disease in humans (SPRINT and ACCORD-BP participants) (HR 1.05, 95% CI 0.74-1.48).

    “not for ESKD (HR 1.05; 95% CI 0.74-1.48; P for interaction = 0.71)”

    HumansSPRINT and ACCORD-BP participants

    Effects of intensive blood pressure control on cardio-kidney outcomes by KDIGO risk categories: a Post Hoc analysis of ACCORD-BP and SPRINT trials

    Hypertension research : official journal of the Japanese Society of Hypertension

More on Intensive blood pressure control

Semaglutide

no changein humans1

1 study
  1. Semaglutide was not clearly linked with end-stage renal disease in adults with ADPKD.

    “No significant differences were observed in ESKD, AKI, or UTI.”

    Humansin adults with ADPKD

    Association of semaglutide use with kidney outcomes in adults with ADPKD: A propensity score-matched real-world study

    Science progress

More on Semaglutide

Lithium

no changein humans1

1 study
  1. Lithium was not clearly linked with end-stage renal disease in adults with bipolar disorder compared with valproate.

    “No significant between-group differences were observed for vascular dementia, mortality, or ESRD.”

    Humansin adults with bipolar disorder compared with valproate

    Lithium versus valproate in bipolar disorder: Associations with dementia, mortality, suicide attempt, and end-stage renal disease in adults aged 45 years and older - a propensity score-matched retrospective cohort study

    Psychiatry research

More on Lithium

Nonsteroidal anti-inflammatory drugs

no changein humans1

1 study
  1. Nonsteroidal anti-inflammatory drugs were not clearly linked with end-stage renal disease in humans.

    “End-stage renal disease (ESRD) incidence was rare and not significant.”

    Humansn = 1,812

    Effects of NSAIDs on Early CKD Development: A 10-Year Population-Based Study Using the Korean Senior Cohort

    Drugs & aging

More on Nonsteroidal anti-inflammatory drugs

Salt intake

no changein humans1

1 study
  1. Salt intake was not clearly linked with end-stage renal disease in humans (younger patients (≤65 years)).

    “No effect of salt intake on ESKD and mortality was observed in younger patients.”

    Humansyounger patients (≤65 years)

    Predictive effect of salt intake on patient and kidney survival in non-dialysis CKD: competing risk analysis in older versus younger patients under nephrology care

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

More on Salt intake

Caloric restriction

downin mice1

1 study
  1. Caloric restriction prevents end-stage renal disease in mice (mosaic Pkd1 conditional knockout).

    “Mice on an RFI diet maintained kidney function and did not progress to end-stage renal disease.”

    Animalsmosaic Pkd1 conditional knockoutreduced food intake dietkidney23% reduction in food intake

    A mild reduction of food intake slows disease progression in an orthologous mouse model of polycystic kidney disease

    American journal of physiology. Renal physiology

More on Caloric restriction

Effects

26

Cellular senescence

upin humans3

3 studies
  1. End-stage renal disease is linked with higher cellular senescence in humans (uremic arteries).

    “Uremic arteries displayed elevated expression of senescence markers (p21CIP1, p16INK4a, and SA-β-gal)”

    Humansuremic arteriesartery

    Early vascular aging in chronic kidney disease: focus on microvascular maintenance, senescence signature and potential therapeutics

    Translational research : the journal of laboratory and clinical medicine

  2. End-stage renal disease is linked with higher cellular senescence in humans.

    “Aging-associated T cell changes are aggravated in ESRD patients”

    HumansT celln = 466

    Premature aging of circulating T cells predicts all-cause mortality in hemodialysis patients

    BMC nephrology

  3. End-stage renal disease is linked with higher cellular senescence in humans.

    “ESRD patients exhibit accelerated immunosenescence in both T cell and monocyte compartments”

    Humans

    A comprehensive characterization of aggravated aging-related changes in T lymphocytes and monocytes in end-stage renal disease: the iESRD study

    Immunity & ageing : I & A

More on Cellular senescence

GNRI and serum albumin

downin humans1

1 study
  1. End-stage renal disease is linked with lower GNRI and serum albumin in humans (HD patients compared with euthyroid controls).

    “lower FT3, FT4, albumin, and GNRI values (all P < 0.05)”

    HumansHD patients compared with euthyroid controlsn = 101

    Thyroid function, nutritional status, inflammation, and sarcopenia in hemodialysis patients: an integrated cross-sectional analysis

    Endocrine connections

More on GNRI and serum albumin

C-reactive protein, IL-6 and TNF-α

upin humans1

1 study
  1. End-stage renal disease is linked with higher C-reactive protein, IL-6 and TNF-α in humans (HD patients compared with euthyroid controls).

    “HD patients were older and had higher TSH, C-reactive protein, IL-6, TNF-α, and leptin levels”

    HumansHD patients compared with euthyroid controlsn = 101

    Thyroid function, nutritional status, inflammation, and sarcopenia in hemodialysis patients: an integrated cross-sectional analysis

    Endocrine connections

More on C-reactive protein, IL-6 and TNF-α

Circulating leucine

downin humans1

1 study
  1. End-stage renal disease is linked with lower circulating leucine in humans (compared with healthy controls; independent metabolomic cohort).

    “demonstrated lower circulating leucine levels and disrupted amino acid correlations in HD patients compared with healthy controls”

    Humanscompared with healthy controls; independent metabolomic cohort

    Combined leucine supplementation and exercise to counteract sarcopenia in patients with end-stage kidney disease undergoing maintenance hemodialysis: a single-center randomized pilot study

    Kidney research and clinical practice

More on Circulating leucine

Physical activity

downin humans1

1 study
  1. End-stage renal disease is linked with lower physical activity in hemodialysis patients (-42% light PA, -77% MVPA, -73% steps).

    “Age- and sex-adjusted geometric means of light-intensity PA, moderate-to-vigorous intensity PA, and steps were 42%, 77%, and 73% lower among hemodialysis patients than community-dwelling adults.”

    Humansin hemodialysis patients

    Accelerometry-Derived Physical Activity Levels and Mortality in Hemodialysis Patients: A Prospective Cohort Study

    American journal of kidney diseases : the official journal of the National Kidney Foundation

AHNAK

downin humans1

1 study
  1. End-stage renal disease is linked with lower AHNAK in humans (end-stage renal disease).

    “Plasma AHNAK protein levels was higher in the sarcopenia group but was lower in the ESRD group.”

    Humansend-stage renal diseaseplasman = 22

    Comparative Analysis of Primary Sarcopenia and End-Stage Renal Disease-Related Muscle Wasting Using Multi-Omics Approaches

    Journal of cachexia, sarcopenia and muscle

More on AHNAK

Epinephrine

upin humans1

1 study
  1. End-stage renal disease is linked with higher epinephrine in humans (end-stage renal disease).

    “Catecholamines, including epinephrine, dopamine and serotonin, are significantly elevated in the plasma of patients within the ESRD group.”

    Humansend-stage renal diseaseplasman = 22

    Comparative Analysis of Primary Sarcopenia and End-Stage Renal Disease-Related Muscle Wasting Using Multi-Omics Approaches

    Journal of cachexia, sarcopenia and muscle

More on Epinephrine

Muscle mass

downin humans1

1 study
  1. End-stage renal disease is linked with lower muscle mass in humans (end-stage renal disease).

    “Muscle mass, handgrip strength and lower limb muscle function significantly lower in the sarcopenia group and the ESRD group compared with those in the control group.”

    Humansend-stage renal diseaseskeletal musclen = 22

    Comparative Analysis of Primary Sarcopenia and End-Stage Renal Disease-Related Muscle Wasting Using Multi-Omics Approaches

    Journal of cachexia, sarcopenia and muscle

Microvascular stiffness

upin humans1

1 study
  1. End-stage renal disease is linked with higher microvascular stiffness in humans.

    “aside from higher stiffness detected in the microcirculation of ESKD participants”

    Humansmicrovasculature

    Early vascular aging in chronic kidney disease: focus on microvascular maintenance, senescence signature and potential therapeutics

    Translational research : the journal of laboratory and clinical medicine

Endothelial function

no changein humans1

1 study
  1. End-stage renal disease was not clearly linked with endothelial function in vivo measurement.

    “In vivo measurement revealed no major difference in endothelial function between ESKD and control group”

    Humansin vivo measurementendothelium

    Early vascular aging in chronic kidney disease: focus on microvascular maintenance, senescence signature and potential therapeutics

    Translational research : the journal of laboratory and clinical medicine

All 26

Upstream

8

Blood pressure

no changein humans1

1 study
  1. Blood pressure was not clearly linked with end-stage renal disease in humans (adjusted hazard ratio 0.95, 95% CI 0.80-1.15).

    “after adjustment for clinical and sociodemographic factors, higher CoV was significantly associated with cardiovascular outcomes (adjusted hazard ratio 1.25, 95% CI 1.04-1.52) but not kidney outcomes (adjusted hazard ratio 0.95, 95% CI 0.80-1.15)”

    Humansvisit-to-visit blood pressure variability in CKD cohort, adjusted for clinical and sociodemographic factors4.5 yearsn = 3,891

    Association of visit-to-visit blood pressure variability with kidney disease progression and cardiovascular outcomes in the chronic renal insufficiency cohort (CRIC)

    Journal of hypertension

More on Blood pressure

C-reactive protein

no changein humans1HR 1.271

1 study
  1. C-reactive protein was not clearly linked with end-stage renal disease in patients with CKD (HR: 1.271 [0.893-1.809]).

    “but not a higher risk of ESKD (HR: 1.271 [0.893-1.809]) versus hsCRP < 2 mg/l during follow-up”

    Humansin patients with CKD

    ESKD, Major Cardiovascular Events, and Death Associated With Systemic Inflammation

    Kidney international reports

More on C-reactive protein

Hypertension

mediatesin humans1

1 study
  1. Hypertension is linked with end-stage renal disease in humans (Mediated excess risk 3.2% (95% CI 1.9%, 4.4%)).

    “The excess risk mediated by diabetes and hypertension was 2.3% (95% CI: 0.8%, 3.9%) and 3.2% (1.9%, 4.4%) for NO2”

    HumansMediation of the association between nitrogen dioxide exposure and incident end-stage kidney disease10 μg/m3 increase in NO2

    Do diabetes and hypertension mediate the association of air pollution with the incidence of end-stage kidney disease? Results from two large European cohorts

    The Science of the total environment

More on Hypertension

Diabetes mellitus

mediatesin humans1

1 study
  1. Diabetes mellitus is linked with end-stage renal disease in humans (Mediated excess risk 2.3% (95% CI 0.8%, 3.9%)).

    “The excess risk mediated by diabetes and hypertension was 2.3% (95% CI: 0.8%, 3.9%) and 3.2% (1.9%, 4.4%) for NO2”

    HumansMediation of the association between nitrogen dioxide exposure and incident end-stage kidney disease10 μg/m3 increase in NO2

    Do diabetes and hypertension mediate the association of air pollution with the incidence of end-stage kidney disease? Results from two large European cohorts

    The Science of the total environment

More on Diabetes mellitus

ADAM7

downin silico1

1 study
  1. ADAM7 protects against end-stage renal disease in silico.

    “MR analyses suggesting a protective role against ESRD and sarcopenia”

    In silico

    Multi-Omics Analysis Identified ADAM7 as a Biomarker and Therapeutic Target for End-Stage Renal Disease

    Kidney & blood pressure research

More on ADAM7

Female sex

no changein humans1HR 1.33

1 study
  1. female sex was not clearly linked with end-stage renal disease in propensity-matched heart failure patients with cardiac amyloidosis on SGLT2 inhibitors (HR 1.33; 95% CI, 0.60–2.93).

    “incident ESRD (HR 1.33; 95% CI, 0.60–2.93)”

    Humansin propensity-matched heart failure patients with cardiac amyloidosis on SGLT2 inhibitors3 yearsn = 466

    Sex-related differences in clinical outcomes among heart failure patients with cardiac amyloidosis on SGLT2i therapy

    AHA Scientific Sessions 2025 abstract

Clinical Frailty Scale

no changein humans1

1 study
  1. Clinical Frailty Scale was not clearly linked with end-stage renal disease in humans (AAV) (P=1.0).

    “There was no significant difference in end stage kidney disease between those with higher (>5) or lower (≤5) CFS (P=1.0)”

    HumansAAVn = 41

    The Limitations of Frailty Assessment Tools in ANCA-Associated Vasculitis

    The Journal of frailty & aging

More on Clinical Frailty Scale

Serum creatine kinase activity

no changein humans1

1 study
  1. Serum creatine kinase activity was not clearly linked with end-stage renal disease in humans.

    “The sCK level was not associated with the risk of ESRD.”

    Humansmedian follow-up 6.0 years

    Low Serum Creatine Kinase Level Predicts Mortality in Patients with a Chronic Kidney Disease

    PloS one

More on Serum creatine kinase activity

Associations

75

SGLT2 inhibitors

downin humans14HR 0.26–0.75

14 studies
  1. SGLT2 inhibitors lower the risk of end-stage renal disease in humans (RR = 0.70, 95% CI: 0.65 to 0.75).

    “In the pooled analysis using 11 trials (SGLT2i = 25,907, placebo = 20,811), there was a substantial decline in the development of ESKD in patients under SGLT2i treatment relative to the placebo group (RR = 0.70, 95% CI: 0.65 to 0.75, I2 = 0.0%, p = 0.92, ).”

    Human trialapproximately 2.4 years

    Effectiveness of SGLT2 inhibitors in slowing chronic kidney disease progression and reducing mortality: a meta-analysis

    Frontiers in pharmacology

  2. SGLT2 inhibitors are linked with a lower risk of end-stage renal disease in humans (continuation for 3 months after TAVI versus discontinuation, propensity-matched cohorts) (55% reduction; HR 0.45, 95% CI 0.25–0.81).

    “a profound 55% reduction in progression to ESRD (HR 0.45, 95% CI 0.25–0.81, p=0.006)”

    Humanscontinuation for 3 months after TAVI versus discontinuation, propensity-matched cohorts1 yearn = 1,104

    Continued sodium-glucose cotransporter-2 inhibitors linked to survival

    ESC Congress 2026 abstract

  3. SGLT2 inhibitors are linked with a lower risk of end-stage renal disease in humans (propensity-matched adults aged 80 years or older with chronic kidney disease).

    “incident dialysis and end-stage renal disease were significantly reduced”

    Humanspropensity-matched adults aged 80 years or older with chronic kidney diseasetwo yearsn = 10,076

    Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitors in the Very Elderly with Chronic Kidney Disease: a Retrospective Cohort Study Using Real-World Data

    medRxivPreprint

  4. SGLT2 inhibitors are associated with end-stage renal disease in humans (patients with diabetes after transcatheter aortic valve replacement).

    “Our study also demonstrated a significant reduction in the risk of end-stage renal disease in the SGLT2i-exposed cohort at the 1-year follow-up.”

    Humanspatients with diabetes after transcatheter aortic valve replacement1-year follow-upn = 9,930

    Diabetes drugs linked to fewer complications after valve replacement

    Journal of the Society for Cardiovascular Angiography & Interventions

  5. SGLT2 inhibitors are linked with a lower risk of end-stage renal disease in humans (compared with DPP-4 inhibitor initiation, intention-to-treat analysis) (HR 0.374, 95% CI 0.157-0.890).

    “lower risk of end-stage renal disease or dialysis (HR 0.374, 95% CI 0.157-0.890)”

    Humanscompared with DPP-4 inhibitor initiation, intention-to-treat analysis

    Real-world effectiveness of SGLT2 inhibitors in adults aged 75 years or older: a target trial emulation

    Age and ageing

  6. SGLT2 inhibitors are linked with a lower risk of end-stage renal disease in humans (non-diabetic heart failure) (HR 0.75, 95% CI 0.63-0.89).

    “ESKD (HR 0.75, 95% CI 0.63-0.89; P = .001).”

    Humansnon-diabetic heart failuremedian follow-up of 1.2 years

    Association of SGLT2 inhibitors and new-onset dementia in non-diabetic patients with heart failure

    European journal of heart failure

  7. SGLT2 inhibitors are linked with a lower risk of end-stage renal disease in humans (type 2 diabetes and liver cirrhosis) (adjusted HR 0.34, 95% CI 0.25-0.47).

    “compared with DPP4i use, SGLT2i treatment was associated with significantly reduced risks of ESKD (adjusted hazard ratio [HR], 0.34; 95% CI, 0.25-0.47)”

    Humanstype 2 diabetes and liver cirrhosismedian 2.3 yearsn = 24,259

    SGLT2 Inhibitor Use and Cardiorenal Outcomes in Type 2 Diabetes With Liver Cirrhosis

    JAMA network open

  8. SGLT2 inhibitors are associated with end-stage renal disease in degenerative aortic stenosis (0.40% vs. 1.0% HR 0.292; 95% CI 0.222-0.384; p < 0.001).

    “end-stage kidney disease (0.40% vs. 1.0% HR 0.292; 95% CI 0.222-0.384; p < 0.001)”

    Humansin degenerative aortic stenosis

    Assessing Potential Valve-Preserving Effects of SGLT2 Inhibitors in Degenerative Aortic Stenosis: A Propensity-Matched Study

    Journal of clinical medicine

  9. SGLT2 inhibitors are associated with end-stage renal disease in humans (Hospitalized Chinese patients with chronic kidney disease; comparison with nonusers) (HR 0.26, 95% CI 0.18-0.37).

    “incidence of ESKD (HR 0.26, 95% CI 0.18-0.37, p < 0.001)”

    HumansHospitalized Chinese patients with chronic kidney disease; comparison with nonusers

    Influence of SGLT2i on Renal Progression in CKD Patients: A Multicenter Real-World Study in China

    Kidney diseases (Basel, Switzerland)

  10. SGLT2 inhibitors are linked with a lower risk of end-stage renal disease in humans (relative to other anti-diabetic agents) (aHR 3.62 to 19.16 for other ADAs versus SGLT2i).

    “Compared to SGLT2i, all ADAs show a significantly higher risk of developing ESRD and all-cause mortality”

    Humansrelative to other anti-diabetic agents

    Cardiorenal Protective Effects of Anti-diabetic Drugs in Early Stage Cardiovascular-Kidney-Metabolic Syndrome: A Multicenter, Time-Varying Analysis

    AHA Scientific Sessions 2025 abstract

All 15

More on SGLT2 inhibitors

Mortality

upin humans7OR 2.31–5.57

7 studies
  1. End-stage renal disease predicts mortality in humans (Older Thai adults with positive screening FOBT) (aHR 2.14, 95% CI 1.22–3.76).

    “Independent mortality predictors included end-stage renal disease (aHR 2.14, 95% CI 1.22–3.76)”

    HumansOlder Thai adults with positive screening FOBT5 yearsn = 709

    Illness burden linked to survival in older Thai adults

    Research SquarePreprint

  2. End-stage renal disease predicts mortality in humans (hip fracture) (aOR 4.64, 95% CI 2.097–10.263).

    “end-stage renal disease (adjusted odds ratio [aOR] 4.64, 95% confidence interval [CI] 2.097–10.263; 4 points)”

    Humanship fracture1-yearn = 1,263

    Development of a Mortality Prediction Score for Patients With Hip Fractures

    Journal of Southeast Asian Orthopaedics

  3. End-stage renal disease is linked with a higher risk of mortality in humans (asymptomatic carotid artery disease undergoing carotid intervention) (23.5% vs. 11.8%, OR 2.31 (95% CI 1.51-3.53)).

    “Mortality was significantly higher in the ESRD group at both 3 years (23.5% vs. 11.8%; OR, 2.31; 95% CI, 1.51-3.53)”

    Humansasymptomatic carotid artery disease undergoing carotid intervention3 yearsn = 329

    Carotid Artery Intervention May Still Be Justified in Asymptomatic Patients with End-Stage Renal Disease

    Annals of vascular surgery

  4. End-stage renal disease is linked with a higher risk of mortality in older adults with type 2 diabetes (HR 2.54, 95% CI 2.33-2.77).

    “the condition with the highest hazard ratio for 3-year mortality was end-stage kidney disease, with an HR of 2.54 (95% CI 2.33-2.77).”

    Humansin older adults with type 2 diabetes

    Development and Validation of a Mortality Risk Prediction Model Using Large-Scale Data from 900,000 Korean Older Adults with Diabetes

    ADA Scientific Sessions 2025 abstract

  5. End-stage renal disease is linked with a higher risk of mortality in nonoperative treatment hip fracture patients (86.84% vs 32.0%).

    “The 1-year mortality rate of the observation group was considerably higher than that of the control group, which was 86.84% and 32.0%, respectively (P < .005).”

    Humansin nonoperative treatment hip fracture patientsn = 113

    Poor prognosis and risk factors of nonoperative treatment hip fracture patients with end-stage renal disease

    Medicine

  6. End-stage renal disease predicts mortality in humans after surgically treated hip fractures.

    “End-Stage-Renal Failure (ESRF), liver failure and COPD were dominant predictors of mortality at 10 years”

    Humansafter surgically treated hip fractures10 yearsn = 766

    Predictors of 10-year Mortality After Hip Fracture Surgery in a Pre-Pandemic Cohort

    Geriatric orthopaedic surgery & rehabilitation

  7. End-stage renal disease raises the risk of mortality in humans after major lower limb amputation (peak OR 5.57).

    “End stage renal disease, heart failure, frailty, and higher-level amputation were all associated with increased mortality, demonstrating peak odds ratios of 5.57, 2.14, 2.25, and 2.30, respectively.”

    Reviewafter major lower limb amputation

    Editor's Choice - Systematic Review, Meta-analysis, and Time to Event Analysis of Contemporary Mortality after Major Lower Limb Amputation for Peripheral Arterial Disease or Diabetes Mellitus

    European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery

GLP-1 receptor agonists

upin humans1downin humans1downin silico1HR 2.12

3 studies
  1. GLP-1 receptor agonists are associated with end-stage renal disease in humans (Cardiovascular risk factors without established ASCVD) (HR 2.12, 95% CI 1.934–2.330 at 5 years; absolute event rates remained low).

    “higher among GLP-1 RA users at 3 years (HR 1.66; 1.486-1.845) and 5 years (HR 2.12; 1.934-2.330).”

    HumansCardiovascular risk factors without established ASCVD5 years

    Blood sugar drugs linked to fewer heart and blood vessel events

    AHA Scientific Sessions 2026 abstract

  2. GLP-1 receptor agonists are linked with a lower risk of end-stage renal disease in humans after propensity score weighting in target trial emulation (5-year risk 1.6% versus 1.9%; risk difference -0.3% (-0.6% to 0%)).

    “end-stage kidney disease (5-year risk: 1.6% versus 1.9%; risk difference: -0.3% (-0.6% to 0%); HR: 0.81 (0.69-0.95))”

    Humansafter propensity score weighting in target trial emulation5-year risk

    Glucagon-like peptide-1 receptor agonists for major cardiovascular and kidney outcomes in type 1 diabetes

    Nature medicine

  3. GLP-1 receptor agonists lower the risk of end-stage renal disease in silico (added to SGLT2i and standard of care in simulated CKD and T2D cohort) (6.4% vs. 7.6%).

    “Adding GLP-1 RA reduced ESRD incidence (6.4% vs. 7.6%) and increased QALYs (8.76 vs. 8.35) compared to SGLT2i + SC alone.”

    In silicoadded to SGLT2i and standard of care in simulated CKD and T2D cohort30-year lifetime horizonn = 10,000

    Cost-Effectiveness of SGLT2i plus GLP-1RAs vs. SGLT2i in Patients with Chronic Kidney Disease

    ADA Scientific Sessions 2025 abstract

More on GLP-1 receptor agonists

Sarcopenia

upin humans3

3 studies
  1. End-stage renal disease is associated with sarcopenia in adult chronic kidney disease patients (28.3% vs 10.0%).

    “prevalence of sarcopenia was significantly higher among patients with ESRD than among those without ESRD (28.3% vs 10.0%, p=0.01)”

    Humansin adult chronic kidney disease patientsn = 120

    Sarcopenia among chronic kidney disease patients attending a renal clinic in Northwest Ethiopia: a cross-sectional study of prevalence, risk factors and clinical implications

    BMJ open

  2. End-stage renal disease is associated with sarcopenia in humans (HD patients compared with euthyroid controls) (48.5 and 26.7% in HD versus 18.1 and 6.0% in controls).

    “Probable and confirmed sarcopenia were more prevalent in HD patients (48.5 and 26.7%) than in controls (18.1 and 6.0%, P = 0.004).”

    HumansHD patients compared with euthyroid controlsn = 101

    Thyroid function, nutritional status, inflammation, and sarcopenia in hemodialysis patients: an integrated cross-sectional analysis

    Endocrine connections

  3. Sarcopenia is linked with a higher risk of end-stage renal disease in people with chronic kidney disease (hazard ratio 1.98 (1.45 to 2.70)).

    “Those with sarcopenia were twice as likely to develop ESRD (hazard ratio: 1.98; 1.45 to 2.70; P < 0.001).”

    Humansin people with chronic kidney diseasen = 8,767

    Association of sarcopenia with mortality and end-stage renal disease in those with chronic kidney disease: a UK Biobank study

    Journal of cachexia, sarcopenia and muscle

More on Sarcopenia

Age-related macular degeneration

upin humans2HR 1.72

2 studies
  1. Age-related macular degeneration is linked with a higher risk of end-stage renal disease in humans (aHR 1.33, 95% CI 1.24-1.44).

    “AMD was associated with 33% increased risk of ESRD (adjusted HR [aHR] 1.33, 95% confidence interval [CI] 1.24-1.44)”

    Humansmean 9.95 years

    Increased end-stage renal disease risk in age-related macular degeneration: a nationwide cohort study with 10-year follow-up

    Scientific reports

  2. End-stage renal disease is associated with age-related macular degeneration in humans (Receiving long-term dialysis; compared with controls without kidney disease) (HR 1.72, 95% CI 1.50–1.97).

    “The hazard ratios for AMD were 1.72, 2.47, and 1.43 for the ESRD, PD, and HD cohorts”

    HumansReceiving long-term dialysis; compared with controls without kidney diseasen = 27,232

    RISK OF AGE-RELATED MACULAR DEGENERATION IN END-STAGE RENAL DISEASE PATIENTS RECEIVING LONG-TERM DIALYSIS

    Retina (Philadelphia, Pa.)

More on Age-related macular degeneration

Alzheimer's disease

upin humans2HR 1.67

2 studies
  1. Alzheimer's disease is linked with a higher risk of end-stage renal disease in humans (time-varying exposure, adjusted for clinical variables and competing risks of death) (HR 1.67, 95% CI 1.34-2.08).

    “the risk of incident ESKD was higher in the AD group than in the nonAD group (hazard ratio [HR], 1.67; 95% confidence interval [CI], 1.34-2.08).”

    Humanstime-varying exposure, adjusted for clinical variables and competing risks of death

    Associations among Alzheimer disease, depressive disorder, and risk of end-stage kidney disease in elderly people

    Kidney research and clinical practice

  2. End-stage renal disease is associated with Alzheimer's disease in patients with end-stage renal disease.

    “the incidence of Alzheimer's disease has also been found to be higher in patients with end-stage renal disease (ESRD) than in the general population.”

    Reviewin patients with end-stage renal disease

    Chronic kidney disease and cognitive impairment

    Geriatrie et psychologie neuropsychiatrie du vieillissement

More on Alzheimer's disease

Frailty

upin humans2

2 studies
  1. Frailty is linked with a higher risk of end-stage renal disease in humans.

    “All stages of frailty significantly increased ESKD rates.”

    Humansn = 819,893

    Associations between frailty trajectories and cardiovascular, renal, and mortality outcomes in chronic kidney disease

    Journal of cachexia, sarcopenia and muscle

  2. End-stage renal disease is associated with frailty in humans (Prevalence assessed using objectively measured CHS criteria) (Pooled prevalence 36.8% (95% CI 29.9–44.1%)).

    “More than one-third of ESRD patients were frail based on the objectively measured CHS criteria”

    ReviewPrevalence assessed using objectively measured CHS criteria

    Prevalence of frailty in end-stage renal disease: a systematic review and meta-analysis

    International urology and nephrology

Bone-specific alkaline phosphatase

upin humans1

1 study
  1. End-stage renal disease is associated with bone-specific alkaline phosphatase in humans (15.57 ± 1.59 pg/mL and 17.24 ± 2.10 pg/mL).

    “By contrast, levels of bone-formative markers were highest in the ESRD groups, specifically bone-specific ALP (15.57 ± 1.59 pg/mL and 17.24 ± 2.10 pg/mL for the ESRD groups with and without the exercise intervention, respectively) and P1NP (1269.12 ± 116.34 pg/mL and 1634.07 ± 174.57 pg/mL for the ESRD groups with and without the exercise intervention, respectively”

    Humans12 weeks

    The comparison of serum bone-turnover markers in different stage of chronic kidney disease and the associated impact of intradialytic cycling in patients with end-stage renal disease

    Aging

  2. End-stage renal disease is associated with bone-specific alkaline phosphatase in humans (chronic kidney disease).

    “Bone-formative marker levels (bone-specific alkaline phosphatase and procollagen type 1 amino-terminal propeptide, P1NP) were higher in ESRD patients than in non-ESRD patients”

    Humanschronic kidney disease

    The comparison of serum bone-turnover markers in different stage of chronic kidney disease and the associated impact of intradialytic cycling in patients with end-stage renal disease

    Aging

More on Bone-specific alkaline phosphatase

Kidney Failure Risk Equation and Kaiser Permanente Northwest equation

mixedin humans1

1 study
  1. Kidney Failure Risk Equation and Kaiser Permanente Northwest equation predicts end-stage renal disease in humans (patients with chronic kidney disease).

    “have also been validated tools in being able to predict risk of end-stage kidney disease in patients with CKD.”

    Reviewpatients with chronic kidney disease

    Identification and risk stratification of chronic kidney disease in primary care

    Postgraduate medicine

More on Kidney Failure Risk Equation and Kaiser Permanente Northwest equation

Normal-BMI MASLD

upin humans1

1 study
  1. Normal-BMI MASLD is associated with end-stage renal disease in humans (Black patients; compared with overweight/obesity-associated MASLD).

    “higher ESRD risk in Black patients”

    HumansBlack patients; compared with overweight/obesity-associated MASLD

    Normal-weight fatty liver disease linked to higher mortality

    The Journal of clinical endocrinology and metabolism

More on Normal-BMI MASLD

Canagliflozin

downin humans1HR 0.535

1 study
  1. Canagliflozin lowers the risk of end-stage renal disease in humans (pooled from the CANVAS and CREDENCE trials) (pooled HR 0.535 (0.392-0.729); 46.5% reduction).

    “Among these trial participants, canagliflozin produced a clinically meaningful, statistically significant 46.5% reduction in end-stage kidney disease.”

    Human trialpooled from the CANVAS and CREDENCE trials

    Canagliflozin lowered kidney failure risk in adults 50 and older

    Diabetes research and clinical practice

More on Canagliflozin

All 75

Trial sponsors

Funding

13 grants since 2017

National Institute on Aging$6.5MNational Institute of Diabetes and Digestive and Kidney Diseases$230KUS Department of Veterans Affairs

Latest

Dec 2025: 17Jan 2026: 46Feb 2026: 34Mar 2026: 52Apr 2026: 18May 2026: 14Jun 2026: 30Jul 2026: 12Aug 2026: 47Sep 2026: 34Oct 2026: 39Nov 2026: 29372 papers in 12 months
Frontiers in Nutrition

Early-life sugar rationing linked to lower kidney disease risk

Among 55,263 UK Biobank participants, exposure before birth alone was linked to lower adult kidney disease risk than no rationing exposure, with a hazard ratio of 0.78.Among 55,263 UK Biobank participants, exposure before birth alone was linked to lower adult kidney disease risk than no rationing exposure, with a hazard ratio of 0.78.

Accepted, not yet published: cohort · 55,263 peopleKidney
AHA Scientific Sessions 2026 Abstract

Protein patterns linked to death and kidney problems in heart failure

An observational study of 1,351 people with heart failure linked two blood protein patterns to death and adverse kidney outcomes beyond standard risk measures.An observational study of 1,351 people with heart failure linked two blood protein patterns to death and adverse kidney outcomes beyond standard risk measures.

Cohort · 1,351 peopleHeart failure

See all 1,112 papers on end-stage renal disease